On the one hand, we designed 5 mg olanzapine rather than NK-1 receptor antagonist-based triplet therapy as the control group because a phase 3 trial showed that olanzapine 10 mg was comparable to aprepitant in the control of CINV, but somnolence is a major side effect[6]. This evidence concerns the gene TACR1 and Coma.